Literature DB >> 19037920

Increased resistance to CD4+CD25hi regulatory T cell-mediated suppression in patients with type 1 diabetes.

J M Lawson1, J Tremble, C Dayan, H Beyan, R D G Leslie, M Peakman, T I M Tree.   

Abstract

Type I diabetes (T1D) is a T cell-mediated autoimmune disease characterized by loss of tolerance to islet autoantigens, leading to the destruction of insulin-producing beta cells. Peripheral tolerance to self is maintained in health through several regulatory mechanisms, including a population of CD4+CD25hi naturally occurring regulatory T cells (T(regs)), defects in which could contribute to loss of self-tolerance in patients with T1D. We have reported previously that near to T1D onset, patients demonstrate a reduced level of suppression by CD4+CD25hi T(regs) of autologous CD4+CD25- responder cells. Here we demonstrate that this defective regulation is also present in subjects with long-standing T1D (> 3 years duration; P = 0.009). No difference was observed in forkhead box P3 or CD127 expression on CD4+CD25hi T cells in patients with T1D that could account for this loss of suppression. Cross-over co-culture assays demonstrate a relative resistance to CD4+CD25hi T(reg)-mediated suppression within the CD4+CD25- T cells in all patients tested (P = 0.002), while there appears to be heterogeneity in the functional ability of CD4+CD25hi T(regs) from patients. In conclusion, this work demonstrates that defective regulation is a feature of T1D regardless of disease duration and that an impaired ability of responder T cells to be suppressed contributes to this defect.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19037920      PMCID: PMC2633239          DOI: 10.1111/j.1365-2249.2008.03810.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  36 in total

1.  Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice.

Authors:  Jeong M Kim; Jeffrey P Rasmussen; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2006-11-30       Impact factor: 25.606

2.  No alterations in the frequency of FOXP3+ regulatory T-cells in type 1 diabetes.

Authors:  Todd Brusko; Clive Wasserfall; Kieran McGrail; Richard Schatz; Hilla Lee Viener; Desmond Schatz; Michael Haller; Jennifer Rockell; Peter Gottlieb; Michael Clare-Salzler; Mark Atkinson
Journal:  Diabetes       Date:  2007-03       Impact factor: 9.461

3.  Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells.

Authors:  Sylvaine You; Mériam Belghith; Stephen Cobbold; Marie-Alexandra Alyanakian; Christine Gouarin; Samia Barriot; Corinne Garcia; Herman Waldmann; Jean-François Bach; Lucienne Chatenoud
Journal:  Diabetes       Date:  2005-05       Impact factor: 9.461

4.  Dynamic changes in CD4+ CD25+(high) T cell apoptosis after the diagnosis of type 1 diabetes.

Authors:  S Glisic-Milosavljevic; T Wang; M Koppen; J Kramer; S Ehlenbach; J Waukau; P Jailwala; S Jana; R Alemzadeh; S Ghosh
Journal:  Clin Exp Immunol       Date:  2007-08-17       Impact factor: 4.330

Review 5.  Translational mini-review series on type 1 diabetes: Immune-based therapeutic approaches for type 1 diabetes.

Authors:  T Staeva-Vieira; M Peakman; M von Herrath
Journal:  Clin Exp Immunol       Date:  2007-04       Impact factor: 4.330

Review 6.  Translational mini-review series on type 1 diabetes: Systematic analysis of T cell epitopes in autoimmune diabetes.

Authors:  T P Di Lorenzo; M Peakman; B O Roep
Journal:  Clin Exp Immunol       Date:  2007-04       Impact factor: 4.330

Review 7.  The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease.

Authors:  B Afzali; G Lombardi; R I Lechler; G M Lord
Journal:  Clin Exp Immunol       Date:  2007-04       Impact factor: 4.330

8.  Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes.

Authors:  Christopher E Lowe; Jason D Cooper; Todd Brusko; Neil M Walker; Deborah J Smyth; Rebecca Bailey; Kirsi Bourget; Vincent Plagnol; Sarah Field; Mark Atkinson; David G Clayton; Linda S Wicker; John A Todd
Journal:  Nat Genet       Date:  2007-08-05       Impact factor: 38.330

9.  Defective regulatory and effector T cell functions in patients with FOXP3 mutations.

Authors:  Rosa Bacchetta; Laura Passerini; Eleonora Gambineri; Minyue Dai; Sarah E Allan; Lucia Perroni; Franca Dagna-Bricarelli; Claudia Sartirana; Susanne Matthes-Martin; Anita Lawitschka; Chiara Azzari; Steven F Ziegler; Megan K Levings; Maria Grazia Roncarolo
Journal:  J Clin Invest       Date:  2006-06       Impact factor: 14.808

10.  CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells.

Authors:  Weihong Liu; Amy L Putnam; Zhou Xu-Yu; Gregory L Szot; Michael R Lee; Shirley Zhu; Peter A Gottlieb; Philipp Kapranov; Thomas R Gingeras; Barbara Fazekas de St Groth; Carol Clayberger; David M Soper; Steven F Ziegler; Jeffrey A Bluestone
Journal:  J Exp Med       Date:  2006-07-03       Impact factor: 14.307

View more
  74 in total

1.  Standardizing T-Cell Biomarkers in Type 1 Diabetes: Challenges and Recent Advances.

Authors:  Simi Ahmed; Karen Cerosaletti; Eddie James; S Alice Long; Stuart Mannering; Cate Speake; Maki Nakayama; Timothy Tree; Bart O Roep; Kevan C Herold; Todd M Brusko
Journal:  Diabetes       Date:  2019-07       Impact factor: 9.461

Review 2.  The development and function of regulatory T cells.

Authors:  Creg J Workman; Andrea L Szymczak-Workman; Lauren W Collison; Meenu R Pillai; Dario A A Vignali
Journal:  Cell Mol Life Sci       Date:  2009-04-24       Impact factor: 9.261

Review 3.  Surrogate end points in the design of immunotherapy trials: emerging lessons from type 1 diabetes.

Authors:  Bart O Roep; Mark Peakman
Journal:  Nat Rev Immunol       Date:  2010-02       Impact factor: 53.106

4.  Frequently Increased but Functionally Impaired CD4+CD25+ Regulatory T Cells in Patients with Oral Lichen Planus.

Authors:  Leilei Zhou; Tianyi Cao; Yufeng Wang; Hui Yao; Guanhuan Du; Guangjie Chen; Xiaoyin Niu; Guoyao Tang
Journal:  Inflammation       Date:  2016-06       Impact factor: 4.092

5.  Dynamic Immune Phenotypes of B and T Helper Cells Mark Distinct Stages of T1D Progression.

Authors:  Tania Habib; S Alice Long; Peter L Samuels; Archana Brahmandam; Megan Tatum; Andrew Funk; Anne M Hocking; Karen Cerosaletti; Michael T Mason; Elizabeth Whalen; David J Rawlings; Carla Greenbaum; Jane H Buckner
Journal:  Diabetes       Date:  2019-03-20       Impact factor: 9.461

Review 6.  T regulatory (Treg) and T helper 17 (Th17) lymphocytes in thyroid autoimmunity.

Authors:  Roberto González-Amaro; Mónica Marazuela
Journal:  Endocrine       Date:  2015-10-16       Impact factor: 3.633

Review 7.  Alteration of regulatory T cells in type 1 diabetes mellitus: a comprehensive review.

Authors:  Tingting Tan; Yufei Xiang; Christopher Chang; Zhiguang Zhou
Journal:  Clin Rev Allergy Immunol       Date:  2014-10       Impact factor: 8.667

8.  Enhanced T cell responses to IL-6 in type 1 diabetes are associated with early clinical disease and increased IL-6 receptor expression.

Authors:  Christian Hundhausen; Alena Roth; Elizabeth Whalen; Janice Chen; Anya Schneider; S Alice Long; Shan Wei; Rebecca Rawlings; MacKenzie Kinsman; Stephen P Evanko; Thomas N Wight; Carla J Greenbaum; Karen Cerosaletti; Jane H Buckner
Journal:  Sci Transl Med       Date:  2016-09-14       Impact factor: 17.956

9.  Increased sensitivity of CD4+ T-effector cells to CD4+CD25+ Treg suppression compensates for reduced Treg number in asymptomatic HIV-1 infection.

Authors:  Georgina Thorborn; Laura Pomeroy; Heidi Isohanni; Melissa Perry; Barry Peters; Annapurna Vyakarnam
Journal:  PLoS One       Date:  2010-02-17       Impact factor: 3.240

10.  The type of responder T-cell has a significant impact in a human in vitro suppression assay.

Authors:  Srikanta Jana; Hope Campbell; Jeffrey Woodliff; Jill Waukau; Parthav Jailwala; Jugal Ghorai; Soumitra Ghosh; Sanja Glisic
Journal:  PLoS One       Date:  2010-12-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.